ArticleMolecular therapy oncolytics2015

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.

Benjamin Ruf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.